Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
International Journal of Laboratory Medicine ; (12): 1052-1055, 2018.
Artículo en Chino | WPRIM | ID: wpr-692792

RESUMEN

Objective To study the expression and significance of serum P53,MMP-7 and MMP-9 in pa-tients with bladder cancer.Methods From March 2015 to March 2017,104 cases of bladder cancer in our hos-pital were analyzed retrospectively,and 52 patients with benign bladder diseases were selected at the same time.According to the severity of the disease,the patients with bladder cancer were divided into the stage Ⅰ -Ⅱ and stage Ⅲ - Ⅳ,and 52 patients with benign lesions were served as the control group.Serum P53 antibody index and absorption rate,serum matrix metalloproteinase-7(MMP-7),serum matrix metalloproteinase -9 (MMP-9)and urine MMP-7 and MMP-9 levels were compared between the three groups.Results The anti-body level and absorption rate of serum P53 in patients with stage Ⅰ - Ⅱ group and stage Ⅲ - Ⅳ group were higher than those of control group(P<0.05).The index of patients in stage Ⅲ-Ⅳ group is higher than that of stage Ⅰ - Ⅱ group(P< 0.05).The serum levels of MMP-7 and MMP-9 in patients with stage Ⅰ - Ⅱ and stage Ⅲ - Ⅳ were higher than those of the control group(P<0.05).The index of patients in stage Ⅲ - Ⅳgroup is higher than that of stage Ⅰ - Ⅱ group(P<0.05).The urine MMP-7 and MMP-9 water in patients with stage Ⅰ - Ⅱ group and stage Ⅲ - Ⅳ group were higher than those of the control group(P<0.05).The indexes of the patients in stage Ⅲ-Ⅳ group were higher than those in stage Ⅰ - Ⅱ group(P<0.05).Conclu-sion The levels of serum P53 antibody index,MMP-7,MMP-9 and urine MMP-7 and MMP-9 were abnormal in bladder cancer patients.Moreover,the higher the stage of bladder cancer,the higher the expression level of these indicators,w hich are helpful in the early diagnosis of bladder cancer.

2.
Chinese Journal of Primary Medicine and Pharmacy ; (12)2006.
Artículo en Chino | WPRIM | ID: wpr-558454

RESUMEN

Objective To present a new seriological method for diagnosing breast carcinoma.Methods Seral anti-p53 antibody was detected with immuno-polymerase chain reation(Immuno-PCR).The expression of p53 in tissue was detected with enzymeimmu-nohistochemistry technique.Results The positive rate of anti-p53 antibody in serum of breast carcinoma was 39.5% and anti-p53 antibody was not found in non-carcinoma and normal controls.The positive rate of anti-p53 antibody was higher than that of non-carcinoma and normal controls(P

3.
The Korean Journal of Laboratory Medicine ; : 168-173, 2005.
Artículo en Coreano | WPRIM | ID: wpr-214447

RESUMEN

BACKGROUND: Mutations of the tumor suppressor gene p53 cause subsequent cellular accumulation of p53 gene product and a specific immunologic response. Detection of circulating antibodies against p53 protein has been evaluated for a tumor marker or prognostic factor for several cancers including those of the breast, stomach, ovary and lung. METHODS: Serum samples from 74 colorectal cancer patients were obtained preoperatively and anti-p53 antibody was measured by enzyme immunoassay (Anti-P53 ELISA II: PharmaCell, France). Carcinoembryonic antigen (CEA) and Carbohydrate antigen (CA) 19-9 were measured in parallel. Tissue p53 protein expression was examined by immunohistochemical staining. RESULTS: Anti-p53 antibodies were positive in the serum from 34% (25/74) of patients, but normal controls were all negative. Anti-p53 antibodies were significantly associated with p53 protein overexpression. CEA and CA19-9 were detected in 38% and 11%, respectively. There was no correlation among anti-p53 antibody, CEA and CA19-9. No differences were found between the anti-p53 antibody positive and negative groups in the following parameters: tumor site, histologic grades, Dukes stages, margin invasion, vessel invasion, lymph node and distant metastasis, and survival duration. CONCLUSIONS: The measurement of serum anti-p53 antibody is not suitable for preoperative markers of prognostic significance, but can be used as a simple serological marker for detection of p53 alteration. There should be more studies of the serum p53 antibody as a possible marker for postoperative monitoring in colorectal cancer.


Asunto(s)
Femenino , Humanos , Anticuerpos , Mama , Antígeno Carcinoembrionario , Neoplasias Colorrectales , Ensayo de Inmunoadsorción Enzimática , Genes p53 , Genes Supresores de Tumor , Técnicas para Inmunoenzimas , Pulmón , Ganglios Linfáticos , Metástasis de la Neoplasia , Ovario , Estómago
4.
The Korean Journal of Laboratory Medicine ; : 15-21, 2004.
Artículo en Coreano | WPRIM | ID: wpr-213941

RESUMEN

BACKGROUND: Several cancer patients have developed antibodies that recognize the overexpressed p53 protein. In some tumor types, the presence of these antibodies is associated with a poor prognosis. Gastric cancer is a highly prevalent disease associated with a high mortality rate, so there is a need for improved serological markers for disease detection and disease behavior. METHODS: To evaluate the clinical relevance of anti-p53 antibodies and tissue p53 protein expression in gastric cancer, we investigated the presence of serum anti-p53 antibodies in 61 gastric cancer patients, using two enzyme-linked immuno-sorbent assay systems (Dianova p53-autoantibodies ELISA Kit, Hamburg, Germany (A); Pharma Cell Anti-p53 ELISA Kit II, Paris, France (B)), and p53 protein expression was immunohistochemically stained. RESULTS: We have detected serum anti-p53 antibodies in 9.8% (6/61), 18.0% (11/61) of gastric cancer patients before operation by using the A and B kit, respectively, but in none of 21 cancer-free individuals. The detectable expression of p53 protein in tissue was recognized in 49.2% (30/61) of gastric cancer patients, and in 100% (6/6) and 72.7% (7/11) of the patients with anti-p53 Ab by using the A and B kit. The presence of anti-p53 antibodies was significantly associated with high tumor stages, lymph node metastasis, advanced cancers, intestinal histological type, larger tumor size and infiltrating type, and short survival. The overexpression of the p53 protein was significantly associated with large sized tumors, advanced cancers, high tumor stage (III, IV), lymph node metastasis, distant metastasis, early death and high recurrence rate, and short survival. A positive rate for gastic CONCLUSIONS: We have shown that anti-p53 antibodies are closely related to p53 protein overexpression in tumor tissues and could be useful not only as a predictor of an unfavorable prognosis before operation, but also as a serological tumor marker for an increase in the detection rate of gastric cancer by a combination assay with anti-p53 antibodies, CEA and CA 19-9, although not as a screening test.


Asunto(s)
Humanos , Anticuerpos , Ensayo de Inmunoadsorción Enzimática , Francia , Alemania , Neoplasias Intestinales , Ganglios Linfáticos , Tamizaje Masivo , Mortalidad , Metástasis de la Neoplasia , Pronóstico , Recurrencia , Neoplasias Gástricas
5.
Journal of the Korean Gastric Cancer Association ; : 206-213, 2003.
Artículo en Coreano | WPRIM | ID: wpr-86898

RESUMEN

PURPOSE: The clinical implication of p53 mutation in gastric cancer is still unclear, as shown by the discordant results that continue to be reported in the literature. MATENRIALS AND METHODS: To assess p53 gene mutation, tumor p53 overexpression, and serum anti-p53 antibody, we employed a polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis, an immunohistochemistry using monoclonal antibody DO-7, and an enzyme-linked immunosorbent assay (ELISA), respectively. RESULTS: Of 169 surgical specimens of gastric cancer, mutation at exon 5~8 of the p53 was identified in 33 (19.5%) and was significantly correlated with lymph node metastasis. Overexpression of p53 was found in 62 specimens (36.7%) and had a significant correlation with tumor differentiation. Serum anti-p53 antibody was positive in 18 patients (10.7%). Twenty-three of the mutated tumors (69.7%) and 39 of the non-mutated tumors (28.7%) displayed immunoreactivity. Twelve of the immunopositive tumors (19.4%) and 6 of the immunonegative tumors produced anti-p53 antibody. These differences were statistically significant (P<0.001 and P=0.005, respectively). There was no significant difference in survival according to the mutation of p53. CONCLUSION: Mutation and overexpression of p53 can be easily detected by immunohistochemistry. However, standardization of the immunohistochemical staining method, as well as guidelines for interpreting the stained result, will produce concordant results and thereby improve clinical application.


Asunto(s)
Humanos , Ensayo de Inmunoadsorción Enzimática , Exones , Genes p53 , Inmunohistoquímica , Ganglios Linfáticos , Metástasis de la Neoplasia , Neoplasias Gástricas
6.
Journal of Environment and Health ; (12)1992.
Artículo en Chino | WPRIM | ID: wpr-546278

RESUMEN

Objective To observe the effect of formaldehyde exposure on the progress of explanted S180 tumour and the serum p53 antibody in mice. Methods 30 male SPF Kunming mice aged 6 weeks were randomly divided into control group,tumour group and formaldehyde group which drunk purified water,purified water contained 0.05% formaldehyde respectively. One week later S180 tumour cells (2?106) were implanted subcutaneously in the left fore armpit in tumour and formaldehyde group mice. The general state (weight,activity and spirit state),the appearing time and progress of solid tumour was recorded. Four weeks later the animal were sacrificed,the weight and volume of the tumour were measured,the serum p53 antibody was examined by ELISA. Results The activity and spirit state was normal in control group. In tumour and formaldehyde group the mice had withered hair and cachexia,such as emaciated,tired,retardation. In formaldehyde group the weight increase was slow in the first and second week,however it was rapid in 3 and 4 week,the appearing time of solid tumour was advanced,the weight,volume of the tumour were higher than those in tumour group(P

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA